{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:16:49Z","timestamp":1793776609922,"version":"4.6.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastoma (GBM) is a poor prognosis grade 4 glioma. After surgical resection, the standard therapy consists of concurrent radiotherapy (RT) and temozolomide (TMZ) followed by TMZ alone. Our previous data on melanoma patients showed that Dendritic Cell vaccination (DCvax) could increase the amount of intratumoral-activated cytotoxic T lymphocytes<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is a single-arm, monocentric, phase II trial in two steps according to Simon\u2019s design. The trial aims to evaluate progression-free survival (PFS) at three months and the safety of a DCvax integrated with standard therapy in resected GBM patients. DCvax administration begins after completion of RT-CTwith weekly administrations for 4 weeks, then is alternated monthly with TMZ cycles. The primary endpoints are PFS at three months and safety. One of the secondary objectives is to evaluate the immune response both\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      (DTH skin test).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>By December 2022, the first pre-planned step of the study was concluded with the enrollment, treatment and follow up of 9 evaluable patients. Two patients had progressed within three months after leukapheresis, but none had experienced DCvax-related G3-4 toxicities Five patients experienced a positive DTH test towards KLH and one of these also towards autologous tumor homogenate. The median PFS from leukapheresis was 11.3 months and 12.2 months from surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This combination therapy is well-tolerated, and the two endpoints required for the first step have been achieved. Therefore, the study will proceed to enroll the remaining 19 patients. (Eudract number: 2020-003755-15\n                      <jats:ext-link>https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-003755-15\/IT<\/jats:ext-link>\n                      )\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1404861","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T16:29:19Z","timestamp":1723739359000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax)"],"prefix":"10.3389","volume":"15","author":[{"given":"Laura","family":"Ridolfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Gurrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Bulgarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Guidoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Fausti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Ranallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Calpona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Tazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Granato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pancisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Foca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Dall\u2019Agata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Bondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Amadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ancarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gamboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Polselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bartolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Maimone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Arpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigino","family":"Tosatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3892\/etm.2021.10844","article-title":"Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review)","volume":"22","author":"Sevastre","year":"2021","journal-title":"Exp Ther Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11940-018-0499-0","article-title":"Quo vadis-do immunotherapies have a role in glioblastoma","volume":"20","author":"Kurz","year":"2018","journal-title":"Curr Treat Options Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.852950","article-title":"Glioblastoma microenvironment: from an inviolable defense to a therapeutic chance","volume":"12","author":"Di Nunno","year":"2022","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02344-4","article-title":"Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment","volume":"22","author":"Rodr\u00edguez P\u00e9rez","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.770390","article-title":"Dendritic cell vaccination of glioblastoma: road to success or dead end","volume":"12","author":"Datsi","year":"2021","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040537","article-title":"A characterization of dendritic cells and their role in immunotherapy in glioblastoma: from preclinical studies to clinical trials","volume":"11","author":"Srivastava","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad105","article-title":"Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005-2022","volume":"5","author":"Oster","year":"2023","journal-title":"Neurooncol Adv"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v8i4","article-title":"Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea","volume":"8","author":"Kong","year":"2017","journal-title":"Oncotarget"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuchi.2021.04.011","article-title":"The efficacy of dendritic cell vaccine for newly diagnosed glioblastoma: A meta-analysis of randomized controlled studies","volume":"67","author":"Liu","year":"2021","journal-title":"Neurochirurgie"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/or.2024.1374513","article-title":"Efficacy and safety of vaccines after conventional treatments for survival of gliomas: A systematic review and meta-analysis","volume":"18","author":"Amanzadeh Jajin","year":"2024","journal-title":"Oncol Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: A phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000356","article-title":"Dendritic cell vaccination for metastatic melanoma: a 14-year mono institutional experience","volume":"27","author":"De Rosa","year":"2017","journal-title":"Melanoma Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1479-5876-11-135","article-title":"Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients","volume":"11","author":"Ridolfi","year":"2013","journal-title":"J Transl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02353","article-title":"Dendritic cell vaccination in metastatic melanoma turns \"Non-T cell inflamed\" Into \"T-cell inflamed\" Tumors","volume":"10","author":"Bulgarelli","year":"2019","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified criteria for radiographic response assessment in glioblastoma clinical trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: a report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605127","article-title":"Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy","volume":"101","author":"Dunn","year":"2009","journal-title":"Br J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac281","article-title":"Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana","volume":"25","author":"Preusser","year":"2023","journal-title":"Neuro Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3390\/cancers15041239","article-title":"Adjuvant vaccination with allogenic dendritic cells significantly prolongs overall survival in high-grade gliomas: results of a phase II trial","volume":"15","author":"Lepski","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"504979","DOI":"10.1155\/2010\/504979","article-title":"Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis","author":"Ridolfi","year":"2010","journal-title":"Clin Dev Immunol"}],"updated-by":[{"DOI":"10.3389\/fimmu.2024.1494021","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1404861\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T03:55:49Z","timestamp":1726718149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1404861\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2024.1404861"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1404861","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"article-number":"1404861"}}